Odin3 v3.12.7 is a small application for Windows Computer which allows you to install or flash the Stock Firmware or any custom package on Samsung smartphones and Tablets.
![]() ![]()
Downloads Bookends (macOS 10.13 or later). This is the current release. The release notes, tutorials (pdf and video), and User Guide are available via the Help menu. FTP site Contains all our formats and filters, which are included in the application download. They are available online if you need a replacement. Download itunes windows, itunes windows, itunes windows download free.
Here on this page, we have managed to share the official and tested version of Odin Downloader Tool i.e Odin3 v3.12.7.
Download Odin3 v3.12.7
Odin Downloader helps you to Flash the Stock Firmware on your Samsung Smartphone and Tablets. It also helps you to flash the Custom Recovery, Root Package, Boot file on your Samsung Devices.
File Name: odin3_v3.12.7.zip
File Size: 1.23 MB How to Use: See Instructions How to Download: See Example Compatible with: Windows Computer ![]()
Readme Once:
[*] Take a backup First: If you are going to use Odin Downloader to flash stock firmware, custom firmware or root file then take a backup first, as during the flashing process your data may be lost. So, to avoid that take a backup of your personal data before using the tool.
[*] How to use Odin: If you want to learn how to use Odin to flash stock firmware or custom firmware then see How to use Odin Downloader.
[*] Samsung Firmware: If you are looking for the original Samsung Firmware then head over to the Samsung Firmware page.
[*] Samsung Combination File: If you are looking for the original Samsung Combination Firmware then head over to the Samsung Combination File page.
[*] Samsung USB Driver: If you are looking for Samsung USB Driver then head over to the Official Samsung USB Driver Website.
[*] Always Scan First: We have officially scanned the odin3_v3.12.7.zip Tool before sharing it online. You can see the Scan Data of odin3_v3.12.7.zip on VirusTotal.
[*] Hotlinking Not Allowed: If you are willing to share the above tool with your friends, or on any website or forums then use the page url. Don’t use the direct file link, as it will be redirected to the homepage of this website.
Coombs positive hemolytic anemia (AIHA) and idiopathic thrombocytopenic purpura (ITP) are well-known complications of chronic lymphocytic leukemia(CLL). Both are autoimmune phenomena thought to be byproducts of the immune system dysregulation manifested in patients with CLL. Rituxan, cyclophosphamide and dexamethasone(RCD) are known to effectively target lymphocytes and inhibit autoimmune processes. We present our data analyzing 18 CLL patients with one or both of these autoimmune processes treated with the RCD regimen between 1998 and 3/2006. These patients consisted of 15 with AIHA alone, 2 with both AIHA and ITP and one with ITP alone.
The RCD cycle consisted of rituximab 375mg/m 2 iv infusion given on day 1, cyclophosphamide 750–1000mg/m 2 iv (depending on CLL tumor burden) on day 2, and dexamethasone 12 mg iv on days 1 and 2, and orally days 3 through 7. These cycles were repeated at intervals of 3–4 weeks, depending upon recovery of blood counts. All 18 patients responded to treatment in terms of hgb, platelets or both. For the first episodes of AIHA (n=17) mean starting hgb was 8.1g/dL (range 4.0–12.1) and mean post-treatment hgb was 13.2 g/dL(range 10.0–15.4)(Table 1). The three patients with ITP had a platelet increase from nadirs of 1,000, 1,000 and 14,000 to 408,000, 161,000 and 135,000, respectively. Mean duration of initial response was 22 months (range 6–41). Nine patients relapsed and were retreated with RCD.
Again, all 9 responded, and had a mean increase in hgb of 5.1g/dL (range 1.4–7.7) with a mean duration of second response of 16 months(range 3–33). Overall, median survival from initiation of RCD was 70 months (95% CI; 46 to an upper limit not-yet determinable, with follow-up to 8/2006).Of 8 patients with post-treatment Coombs data available for the first episode of AIHA, 4 (50%) converted to Coombs negativity (Table2) and had a mean duration of response of 23.0 months (range 12–41) vs 8.8 months for those who did not convert(range 6–11). In all AIHA episodes (including repeat episodes) with post-treatment Coombs data available (n=18), 6 of 18 (33%) converted to Coombs negativity.
The mean duration of response was 19.8 months (range 6–41) for all episodes with conversion to Coombs negativity, vs 7.0 months for those without(range 3–12). This finding that Coombs conversion portends a longer duration of response suggests treatment goals for AIHA should be a conversion to Coombs negative, and not stopped with recovery of hgb.
![]() Comments are closed.
|
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |